This Government Contract opportunity from Department Of Defense was posted on September 18, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

NOTICE OF INTENT TO SOLE SOURCE for the Development of a Handheld Device for Rapid Assessment of Burn Sepsis Risk

Closed

HT9426-26-NOI-045255Federal

Submission Closed11/02/2026, 03:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714

New

Grant

In Vivo Efficacy and Toxicology StudiesThis subcontract, titled In Vivo Efficacy and Toxicology Studies, supports the National Institutes of Health and the Department of Health and Human Services by providing preclinical validation of biologic therapies for prime contractors on NIH/NINDS ADRD projects. The scope of work involves executing in vivo efficacy, safety pharmacology, and toxicology studies utilizing translationally appropriate animal models specifically for Alzheimer's and Frontotemporal Dementia. To fulfill the requirements, the contractor must utilize GLP-compliant toxicology lab facilities to ensure regulatory standards are met. The primary deliverables include comprehensive preclinical validation reports and detailed toxicology data packages necessary for Investigational New Drug submission. The project is categorized under NAICS code 541714, with a response deadline set for October 10, 2028.

National Institutes Of Health

POSTED

DEADLINE

Genome Editing Construct and Delivery System OptimizationThis subcontract focuses on the design and optimization of genome editing constructs and biologic delivery systems to support prime contractors on NIH/NINDS genomic therapy projects. The scope of work involves utilizing CRISPR/Cas technology along with viral and non-viral vectors to refine editing constructs and delivery mechanisms. The selected provider will be responsible for assessing critical metrics including bioactivity, target engagement, durability, pharmacokinetics, and bioavailability. The final deliverables for this engagement consist of optimized therapeutic leads accompanied by comprehensive bioactivity and pharmacokinetics data reports.

National Institutes Of Health

POSTED

DEADLINE

NCI Research Specialist (Clinician Scientist)The NCI Research Specialist subcontract involves providing leadership and implementation services for National Cancer Institute funded clinical trials on behalf of prime contractors. The selected clinician scientist will be responsible for writing and revising protocols for national cancer clinical trials, managing trials within a clinical trials office, and recruiting patients. Additionally, the role requires active participation in NCI scientific review, monitoring, and steering committees. Candidates must possess clinician scientist status and demonstrated experience in cancer clinical research. The contract requires a dedicated effort ranging from 2.4 to 4.8 person-months per year. This opportunity is associated with the National Institutes of Health under the Department of Health and Human Services, with a response deadline set for February 20, 2029.

National Institutes Of Health

POSTED

DEADLINE

Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)

Solicitation # RFA-NS-28-012

The National Institutes of Health, under the Department of Health and Human Services, has issued solicitation RFA-NS-28-012 to support the translation of genome editing and biologic therapies for Alzheimer's Disease-Related Dementias (ADRD). This includes Frontotemporal Dementia, Lewy Body Dementias, Vascular Contributions to Cognitive Impairment and Dementia, and Multiple Etiology Dementias. The program funds the entire translational pipeline, from therapeutic lead optimization and drug product development to IND-enabling studies and early first-in-human clinical evaluations. Key activities include optimizing editing constructs and delivery systems, demonstrating in vivo efficacy, conducting safety pharmacology and toxicology studies, and developing scalable manufacturing processes that align with regulatory expectations. The agency intends to commit 6 million dollars in both fiscal years 2028 and 2029, with an expected three awards and a maximum project period of five years. Individual annual budget caps are set at 1.3 million dollars in direct costs, increasing to 2.5 million dollars for projects involving clinical trials. Awards are governed by the Public Health Service Act and federal regulations 42 CFR Part 52 and 2 CFR Part 200. Evaluation is based on an Overall Impact Score considering significance, innovation, approach, investigator expertise, and environment, with a specific focus on the Target Product Profile and the use of quantitative Go/No-Go milestones. Eligible applicants include small businesses and other for-profit organizations. Requirements for submission include active registration in the System for Award Management, a Unique Entity Identifier, and eRA Commons accounts. Awardees must adhere to strict cybersecurity incident reporting protocols, notifying the agency within 48 hours of discovery, and must register applicable clinical trials with ClinicalTrials.gov. The solicitation features multiple application cycles with deadlines extending through October 10, 2028, and earliest start dates ranging from December 2027 to July 2029.

National Institutes Of Health

POSTED

DEADLINE

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

Solicitation # PAR-28-042

Solicitation PAR-28-042, issued by the National Institutes of Health under the Department of Health and Human Services, is a funding opportunity designed to support the analytical and clinical validation of molecular, cellular, and imaging biomarkers and assays for cancer. The program focuses on tools for cancer detection, diagnosis, prognosis, monitoring, and the prediction of treatment response or toxicity. Funding is available through either a phased UH2/UH3 mechanism or a standalone UH3 mechanism to facilitate laboratory optimization and clinical validation using human samples. Key deliverables include the demonstration of assay results associated with clinical endpoints, the establishment of statistical cut-off values, and the definition of sensitivity and specificity. All clinical laboratories must adhere to CLIA, GLP, or ISO 17025 standards. Awards are determined via a peer review system based on an overall impact score, evaluating the importance of the research, rigor and feasibility of the approach, and the expertise of the investigators and their environment. Specific evaluation criteria include the clarity of milestones for transitioning from UH2 to UH3 phases and the adequacy of commercialization plans. Eligible applicants include small businesses, for-profit organizations, higher education institutions, and 501(c)(3) nonprofits. Applicants must maintain active registrations in SAM.gov, eRA Commons, and Grants.gov. Additionally, recipients must comply with strict cybersecurity incident reporting requirements, notifying the agency within 48 hours of discovery, and ensure all human subject protocols are reviewed by an Institutional Review Board or Independent Ethics Committee.

National Institutes Of Health

POSTED

DEADLINE

Insect Taxonomy and Identification SpecialistThis subcontract opportunity is for an Insect Taxonomy and Identification Specialist to support prime contractors on USDA Forest Health Protection projects through the Northern Research Station. The selected specialist will perform professional taxonomic screening and identification of raw insect trap samples, specifically focusing on species-level identification of wood-boring beetles and wood wasps, as well as identifying Coleoptera and select Hemiptera to the lowest taxonomic level. The work requires the use of taxonomic keys and high-powered microscopy, with final identification reports delivered in Word or PDF format. The solicitation was posted on November 2, 2026, with a response deadline of December 3, 2026. Classified under NAICS code 541714, the performance of this contract is associated with zip code 26505. Interested parties can find further details via the provided government workspace link.

Northern Research Station

POSTED

DEADLINE

Sanger and High-Throughput DNA Sequencing ServicesThis subcontract for the National Institutes of Health Olao involves providing Sanger and high-throughput DNA sequencing services for prime contractors on NIH/NIEHS projects. The scope of work includes executing whole-plasmid sequencing on yeast colonies, plasmid DNA, and PCR-generated samples derived from recombinant, human, and rodent DNA sources. To ensure precision, the contractor must utilize automated DNA sequencers and PCR thermocyclers equipped with electronic barcode tracking, while maintaining Phred-equivalent quality scores greater than 20 and delivering secure data files. The project is categorized under NAICS code 541714 and will be performed in Durham, North Carolina. Interested parties should note the response deadline of November 12, 2026, for this specialized genomic services requirement.

National Institutes Of Health Olao

POSTED

DEADLINE

DNA Sequencing Service

Solicitation # PCA-NIEHS-00080

The National Institutes of Health, through the National Institute of Environmental Health Sciences, is issuing a Small Business Sources Sought notice for solicitation PCA-NIEHS-00080 to identify capable providers for an indefinite-delivery indefinite-quantity contract. The requirement is for DNA sequencing services and associated bioinformatics support, primarily utilizing Sanger sequencing with a smaller volume of high-throughput whole-plasmid sequencing. The estimated workload is between 2,000 and 3,000 samples per month, including yeast colonies, plasmid DNA, and PCR-generated samples from human and rodent species. The intended period of performance is five years from the date of award, with a potential six-month extension per FAR 52.217-8. The selected contractor must provide a web-based ordering and tracking system, all necessary sample collection and shipping materials, and a reliable transportation method for samples from the NIEHS campus in Research Triangle Park, North Carolina. Key technical requirements include maintaining a Phred-equivalent quality score greater than 20 for sequencing and ensuring successful PCR amplification produces a single DNA band of the expected size. The contractor is responsible for preserving remaining DNA for at least 180 days and returning unused primers to the government. Administrative requirements include submitting invoices within ten business days of the billing cycle and maintaining strict confidentiality of all sequencing data. This notice is specifically targeting small business concerns, including 8(a), SDB, WOSB, HUBZone, VOSB, and SDVOSB designations. Interested parties must submit a capability statement of no more than seven pages, including their UEI, TIN, and business size certification, to Luz Casey by November 12, 2026.

National Institutes Of Health Olao

POSTED

DEADLINE

USDA SBIR/STTR Topic 8.2 — Plant Production and Protection - Biology

Solicitation # USDA-NIFA-TOPIC-8.2

The USDA National Institute of Food and Agriculture is soliciting proposals under Topic 8.2 for Plant Production and Protection - Biology. This initiative focuses on advancing crop production and protection through the development of innovative plant breeding methods, diagnostic technologies for diseases, and the creation of new food and non-food crop plants. Research efforts are directed toward improving plant characteristics to mitigate biotic and abiotic stresses, developing new genotypes for commercial applications, and creating tools to support the health of natural and domesticated pollinators. This opportunity is a total small business set-aside under the SBIR/STTR mandate, restricting eligibility to companies with fewer than 500 employees. Managed by the United States Department of Agriculture, the program is led by Dr. Christopher Philips. Interested parties can find further details and application guidelines through the NIFA website.

National Institute of Food and Agriculture

POSTED

DEADLINE

Clinical Trial Management and ExecutionThe Clinical Trial Management and Execution subcontract, issued by the FDA Office of Acquisition and Grant Services under the Department of Health and Human Services, focuses on the operational and clinical execution of human subject research for FDA regulatory science projects. The selected provider will be responsible for managing patient recruitment, trial monitoring, and data collection across various clinical sites, ensuring all activities strictly adhere to Good Clinical Practice guidelines and Institutional Review Board approvals. Key deliverables for this engagement include the submission of clinical study reports, comprehensive patient data sets, and detailed trial outcome summaries. Interested parties should note that the response deadline for this opportunity is January 22, 2027, and the work falls under NAICS code 541714.

FDA Office Of Acq Grant Svcs

POSTED

DEADLINE

FY27 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science

Solicitation # FDABAA-27-00123

The FY27 FDA Broad Agency Announcement (BAA), solicitation number FDABAA-27-00123, seeks basic and applied research and development proposals to advance regulatory science and innovation. Managed by the FDA Office of Acquisitions and Grant Services, this initiative aims to utilize capabilities from industry and academia to improve technologies, materials, processes, and methods that support the FDA's mission to protect and promote national health. The BAA is open to all responsible sources, with strong encouragement for small business participation. Proposals are evaluated based on overall best value, focusing on scientific and technical merit, the degree of innovation, the feasibility of proposed plans, and the potential to overcome critical barriers in the field. Submissions must be delivered as searchable PDFs via email by January 22, 2027, at 5:00 PM EST. The application process requires a concept paper limited to three pages and a full proposal divided into a technical volume (50-page limit) and a cost volume. Key requirements include valid SAM.gov registration, adherence to strict page limits, and the provision of detailed key personnel qualifications. Awardees must comply with specific regulatory standards, including Good Manufacturing Practice (GMP), Good Laboratory Practice (GLP), and Good Clinical Practice (GCP) where applicable. Additionally, contractors must maintain strict organizational conflict of interest disclosures and provide monthly technical progress reports. Non-small business concerns submitting proposals exceeding 900,000 dollars are required to provide a Small Business Subcontracting Plan.

FDA Office Of Acq Grant Svcs

POSTED

DEADLINE

Biostatistical Analysis for Epidemiological and Experimental StudiesThis subcontract involves providing biostatistical analysis for epidemiological and experimental study datasets on behalf of prime contractors working with the Washington State Department of Labor and Industries. The scope of work includes performing detailed data analysis via encrypted electronic file transfers and delivering comprehensive analysis reports along with formal certification of data disposition. To qualify for this engagement, the contractor must complete the Washington State Institutional Review Board training for the Protection of Human Subjects in Research. The project is categorized under NAICS code 541714 and will be performed across multiple counties. Interested parties must submit their responses by December 21, 2026.

Department of Labor & Industries

POSTED

5 days ago

DEADLINE

in about 2 months

AI Contract Overview

The Defense Health Agency, on behalf of the Walter Reed Army Institute of Research, has issued a Notice of Intent to award a sole source Cost Plus Fixed-Fee Research and Development contract to CFD Research Corporation. The objective is to develop a RapiOmics assay prototype for the SeptiBurnAlert system, creating a handheld device for the rapid detection and prevention of sepsis in burn victims. The required platform must be capable of delivering results from a single drop of blood in approximately one hour while utilizing minimal electrical power and requiring no special handling, storage, or significant intervention. This action is categorized under NAICS code 541714 for Biotechnology Research and Development. While the agency intends to proceed with CFD Research Corporation, it is seeking capability statements from other potential sources to determine if competitive procurement is in the government's best interest. Interested organizations must submit a tailored capability statement of no more than ten pages in bullet format, including organizational details and a Unique Entity ID, to Nicole Applegate by November 02, 2026.